GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (OTCPK:DNPUF) » Definitions » Price-to-Free-Cash-Flow

Sumitomo Pharma Co (Sumitomo Pharma Co) Price-to-Free-Cash-Flow : N/A (As of Apr. 26, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Sumitomo Pharma Co Price-to-Free-Cash-Flow?

As of today (2024-04-26), Sumitomo Pharma Co's share price is $2.70. Sumitomo Pharma Co's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.15. Hence, Sumitomo Pharma Co's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Sumitomo Pharma Co's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, Sumitomo Pharma Co's highest Price-to-Free-Cash-Flow Ratio was 35.07. The lowest was 4.79. And the median was 15.18.

DNPUF's Price-to-Free-Cash-Flow is not ranked *
in the Drug Manufacturers industry.
Industry Median: 21.89
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Sumitomo Pharma Co's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-1.03. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-5.15.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Sumitomo Pharma Co was -535.60% per year.

During the past 13 years, Sumitomo Pharma Co's highest 3-Year average Free Cash Flow per Share Growth Rate was 79.30% per year. The lowest was -41.50% per year. And the median was -0.20% per year.


Sumitomo Pharma Co Price-to-Free-Cash-Flow Historical Data

The historical data trend for Sumitomo Pharma Co's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sumitomo Pharma Co Price-to-Free-Cash-Flow Chart

Sumitomo Pharma Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.38 17.01 6.13 27.05 -

Sumitomo Pharma Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.97 - - - -

Competitive Comparison of Sumitomo Pharma Co's Price-to-Free-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sumitomo Pharma Co's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Sumitomo Pharma Co's Price-to-Free-Cash-Flow falls into.



Sumitomo Pharma Co Price-to-Free-Cash-Flow Calculation

Sumitomo Pharma Co's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=2.70/-5.148
=N/A

Sumitomo Pharma Co's Share Price of today is $2.70.
Sumitomo Pharma Co's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.15.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Sumitomo Pharma Co  (OTCPK:DNPUF) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Sumitomo Pharma Co Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Sumitomo Pharma Co's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Sumitomo Pharma Co (Sumitomo Pharma Co) Business Description

Traded in Other Exchanges
Address
6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.